Monday Oct 26 | Circulation
Letter by Choi et al Regarding Article, "Effects of the Selective...
We read with great interest the subgroup analyses of the Raloxifene use for the Heart trial.1 Although this post hoc analysis did not show benefit of raloxifene for any prespecified group, we believe that one particular subgroup, not defined in this study, may benefit from raloxifene in the reduction of coronary outcomes.
Breast Cancer Prevention: Food and Exercise
You cannot control some things that put you at risk for breast cancer , such as your age and being female.
Eli Lilly Loses Bid for Hearing on Evista Drug Before Canada's High Court
Eli Lilly & Co. lost a bid for a hearing before Canadaa s highest court on whether its patent for the Evista osteoporosis treatment is valid as the company tried to block Apotex Inc.
treating osteoporosis with evista versus fosamax
My mother ,71 years old, has been use Steroid drug for serious Asthma for many years.
How many women must be treated to avert one case?
In his article about chemoprevention of breast cancer, Dr. Goldstein provided relative-risk tables.
Canada: The Federal Court Of Appeal Recently Released An Important...
Canada: The Federal Court Of Appeal Recently Released An Important Decision On The Doctrine Of Sound Prediction and David Tait Facts Eli Lilly's '356 patent claims raloxifene and other benzothiophenes for use in treating or preventing osteoporosis or bone loss, particularly in post-menopausal females, and particularly without eliciting significant ...
Teva Provides Update On Generic Evista(R) Litigation
Teva Pharmaceutical Industries Ltd. announced that the U.S. District Court for the Southern District of Indiana has issued a decision invalidating two patents listed in the FDA's Orange Book for Eli Lilly's Evista Tablets in litigation concerning Teva's abbreviated new drug application to market a generic version.
Judge upholds Lilly's Evista patent
A federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.'s drug Evista, the company announced late yesterday.
Eli Lilly Wins Ruling on Evista Patent, Teva Can't Market Generic Version
Eli Lilly & Co. won a ruling on the validity of patents for its Evista osteoporosis treatment, blocking an attempt by Teva Pharmaceutical Industries Ltd.
U.S. District Court Upholds Validity of Lilly's Evista Patents Through 2014
The U.S. District Court for the Southern District of Indiana today upheld Eli Lilly and Company's method-of-use patents on Evista .
Earnings Estimates Revisions They're the most powerful force driving stock prices, and the key to the Zacks Rank's market-beating track record.
Although Tamoxifen, Raloxifen And Tibolone Dramatically Reduce The...
Three drugs that reduce a woman's chance of getting breast cancer also have been shown to cause adverse effects, according to a new report from the Agency for Healthcare Research and Quality , U.S. Department of Health & Human Services.
Medications effective in reducing risks for breast cancer can also cause serious side effects
Three drugs that reduce a woman's chance of getting breast cancer also have been shown to cause adverse effects, according to a new report from the Agency for Healthcare Research and Quality , U.S. Department of Health & Human Services.
Drugs help prevent breast cancer but pose risks too
Women at high risk of breast cancer can often lower that risk by taking medication, including drugs like tamoxifen or the osteoporosis drug raloxifene .
Taking Evista is worth the risk
DEAR DR. DONOHUE: My doctor recently put me on Evista. I had a complete hysterectomy when I was 40 years old.
Agency for Healthcare Research and Qu...
Medications Effective in Reducing Risk of Breast Cancer but Increase...
Three drugs, including tamoxifen, reduce a woman's chance of getting breast cancer, but each drug carries distinct potential harms of its own, according to a new report from the Department of Health & Human Services' Agency for Healthcare Research and Quality .
Question Of The Week: Is Your Osteoporosis Treatment Working Or Not?
Some of us are doing well on our osteoporosis treatment and some of us aren't. For those who aren't seeing gains in bone density, this can be extremely discouraging and we'd like to come up with some ideas for you that may help.
Reader questions osteopenia medicines, which have side effects
I am concerned about a decision I have to make soon regarding Reclast or Forteo for my osteopenia.
Pharma's Next Home Run Drug Could Be 4 Singles Instead
As they pursue home run products, drugmakers also seek the pharmaceutical equivalents of a baseball utility infielder -- a compound that works on several diseases or conditions.
Daiichi Sankyo and Ranbaxy Leverage New Business Model with Launch of Evista in Romania
TOKYO, Gurgaon, India, September 1, 2009 - Daiichi Sankyo Company Limited and Ranbaxy Laboratories Limited announced today that Terapia S.A. , a subsidiary of Ranbaxy in Romania, will market the osteoporosis medication, Evista in Romania.
Also on Topix